Georgia Tech-led effort to improve support device options for end-stage heart failure
News | Heart Failure
The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
News | Stents
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease
News | FDA
FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional ...

Home March 08, 2024
Home
Cinematic Reality app enables interaction with realistic renderings of human anatomy
News | Information Technology
Siemens Healthineers Launches Cinematic Reality App for Apple Vision Pro

March 7, 2024 — Siemens Healthineers has launched an app designed for Apple Vision Pro that enables users such as ...

Home March 07, 2024
Home
The company will showcase AI-enabled innovations and digital solutions that enhance clinical decision making and provide personalized patient care
News | Artificial Intelligence
GE HealthCare to Spotlight Industry-Leading AI-Enabled Portfolio and Digital Solutions at HIMSS 2024

March 7, 2024 — GE HealthCare will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled ...

Home March 07, 2024
Home
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events
News | FDA
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

March 7, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 07, 2024
Home
The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd Annual Scientific Session & Expo, ACC.24, including U.S. Food and Drug Administration Commissioner Robert M. Califf, MD, MACC, among a host of highly-regarded cardiovascular thought leaders and practitioners during the April 6-8 meeting in Atlanta, GA.
News | ACC
FDA Commissioner, Host of Cardiovascular Leaders to Offer Keynote Addresses at ACC.24

March 7, 2024 — The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd ...

Home March 07, 2024
Home
Matt Renner, President of North America and Global Startups at Google Cloud, is one of several keynote to be featured during the HIMSS 2024, the Global Conference and Exhibition of the Healthcare Information and Management Systems Society (HIMSS) to be held March 11-15 in Orlando, FL.
News | HIMSS
Google Cloud Leader and High-Profile Keynote Speakers to be Featured at HIMSS24

March 7, 2024 — With just days to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare ...

Home March 07, 2024
Home
Among the many notable trends in CT, one of the fastest growing is the coronary CT angiography market, as witnessed at RSNA23
Feature | CT Angiography (CTA) | By Melinda Taschetta-Millane
The Evolving Computed Tomography Market

Computed Tomography (CT) continues to be a rapidly evolving technology with many new advancements, as displayed and ...

Home March 07, 2024
Home
An AMA letter sent to Secretary Bacerra outlines ongoing concerns of physicians amidst the cybersecurity incident that has impacted Change Healthcare
News | Cybersecurity
As Cyberattack Jeopardizes Physician Practices, AMA Demands Action

March 6, 2024 — As the cyber-takedown of Change Healthcare has forced medical practices to go without revenue for a ...

Home March 06, 2024
Home
Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
News | FDA
Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

March 6, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...

Home March 06, 2024
Home
Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation for their ECGvision-TTR Technology
News | FDA
Ensight-AI Awarded FDA’s Breakthrough Device Designation for Its ECGVision-TTR Technology for Early Detection of ATTR-Cardiomyopathy

March 6, 2024 — Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of ...

Home March 06, 2024
Home
Bodyport Inc., a biomarker-guided predictive care company, has presented data showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.
News | Cardiovascular Clinical Studies
Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote Heart Failure Monitoring at Technology and Heart Failure Therapeutics (THT) Conference

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
Lantheus announced that the U.S. Food and Drug Administration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly.
News | FDA
Lantheus Announces the FDA Approval of DEFINITY as Ultrasound Enhancing Agent for Use in Certain Pediatric Cardiovascular Patients

March 6, 2024 — Lantheus Holdings, Inc. (Lantheus), a radiopharmaceutical company, has announced that the U.S. Food and ...

Home March 06, 2024
Home
Konica Minolta's Exa Platform
Feature | PACS | By Melinda Taschetta-Millane
The Emergence of Cloud-based PACS, and Other Trends

Picture archiving and communication systems (PACS) play a crucial role in modern radiology by providing a digital ...

Home March 06, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now